Copyright Reports & Markets. All rights reserved.

Global Proton Pump Inhibitors for Gastric Acid Therapy Market Growth 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for Proton Pump Inhibitors for Gastric Acid Therapy by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for Proton Pump Inhibitors for Gastric Acid Therapy by Country/Region, 2017, 2022 & 2028
  • 2.2 Proton Pump Inhibitors for Gastric Acid Therapy Segment by Type
    • 2.2.1 Dexlansoprazole
    • 2.2.2 Esomeprazole
    • 2.2.3 Lansoprazole
    • 2.2.4 Omeprazole
    • 2.2.5 Pantoprazole
    • 2.2.6 Rabeprazole
  • 2.3 Proton Pump Inhibitors for Gastric Acid Therapy Sales by Type
    • 2.3.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales Market Share by Type (2017-2022)
    • 2.3.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Sale Price by Type (2017-2022)
  • 2.4 Proton Pump Inhibitors for Gastric Acid Therapy Segment by Application
    • 2.4.1 Hospital Pharmacy
    • 2.4.2 Retail Pharmacy
    • 2.4.3 Other
  • 2.5 Proton Pump Inhibitors for Gastric Acid Therapy Sales by Application
    • 2.5.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Sale Market Share by Application (2017-2022)
    • 2.5.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Sale Price by Application (2017-2022)

3 Global Proton Pump Inhibitors for Gastric Acid Therapy by Company

  • 3.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Breakdown Data by Company
    • 3.1.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Annual Sales by Company (2020-2022)
    • 3.1.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales Market Share by Company (2020-2022)
  • 3.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Annual Revenue by Company (2020-2022)
    • 3.2.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Company (2020-2022)
    • 3.2.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue Market Share by Company (2020-2022)
  • 3.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Sale Price by Company
  • 3.4 Key Manufacturers Proton Pump Inhibitors for Gastric Acid Therapy Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Proton Pump Inhibitors for Gastric Acid Therapy Product Location Distribution
    • 3.4.2 Players Proton Pump Inhibitors for Gastric Acid Therapy Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Proton Pump Inhibitors for Gastric Acid Therapy by Geographic Region

  • 4.1 World Historic Proton Pump Inhibitors for Gastric Acid Therapy Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Annual Revenue by Geographic Region
  • 4.2 World Historic Proton Pump Inhibitors for Gastric Acid Therapy Market Size by Country/Region (2017-2022)
    • 4.2.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Annual Revenue by Country/Region
  • 4.3 Americas Proton Pump Inhibitors for Gastric Acid Therapy Sales Growth
  • 4.4 APAC Proton Pump Inhibitors for Gastric Acid Therapy Sales Growth
  • 4.5 Europe Proton Pump Inhibitors for Gastric Acid Therapy Sales Growth
  • 4.6 Middle East & Africa Proton Pump Inhibitors for Gastric Acid Therapy Sales Growth

5 Americas

  • 5.1 Americas Proton Pump Inhibitors for Gastric Acid Therapy Sales by Country
    • 5.1.1 Americas Proton Pump Inhibitors for Gastric Acid Therapy Sales by Country (2017-2022)
    • 5.1.2 Americas Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Country (2017-2022)
  • 5.2 Americas Proton Pump Inhibitors for Gastric Acid Therapy Sales by Type
  • 5.3 Americas Proton Pump Inhibitors for Gastric Acid Therapy Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Proton Pump Inhibitors for Gastric Acid Therapy Sales by Region
    • 6.1.1 APAC Proton Pump Inhibitors for Gastric Acid Therapy Sales by Region (2017-2022)
    • 6.1.2 APAC Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Region (2017-2022)
  • 6.2 APAC Proton Pump Inhibitors for Gastric Acid Therapy Sales by Type
  • 6.3 APAC Proton Pump Inhibitors for Gastric Acid Therapy Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe Proton Pump Inhibitors for Gastric Acid Therapy by Country
    • 7.1.1 Europe Proton Pump Inhibitors for Gastric Acid Therapy Sales by Country (2017-2022)
    • 7.1.2 Europe Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Country (2017-2022)
  • 7.2 Europe Proton Pump Inhibitors for Gastric Acid Therapy Sales by Type
  • 7.3 Europe Proton Pump Inhibitors for Gastric Acid Therapy Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Proton Pump Inhibitors for Gastric Acid Therapy by Country
    • 8.1.1 Middle East & Africa Proton Pump Inhibitors for Gastric Acid Therapy Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa Proton Pump Inhibitors for Gastric Acid Therapy Sales by Type
  • 8.3 Middle East & Africa Proton Pump Inhibitors for Gastric Acid Therapy Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Proton Pump Inhibitors for Gastric Acid Therapy
  • 10.3 Manufacturing Process Analysis of Proton Pump Inhibitors for Gastric Acid Therapy
  • 10.4 Industry Chain Structure of Proton Pump Inhibitors for Gastric Acid Therapy

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 Proton Pump Inhibitors for Gastric Acid Therapy Distributors
  • 11.3 Proton Pump Inhibitors for Gastric Acid Therapy Customer

12 World Forecast Review for Proton Pump Inhibitors for Gastric Acid Therapy by Geographic Region

  • 12.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Market Size Forecast by Region
    • 12.1.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Forecast by Region (2023-2028)
    • 12.1.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Proton Pump Inhibitors for Gastric Acid Therapy Forecast by Type
  • 12.7 Global Proton Pump Inhibitors for Gastric Acid Therapy Forecast by Application

13 Key Players Analysis

  • 13.1 Takeda
    • 13.1.1 Takeda Company Information
    • 13.1.2 Takeda Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.1.3 Takeda Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 Takeda Main Business Overview
    • 13.1.5 Takeda Latest Developments
  • 13.2 Pfizer
    • 13.2.1 Pfizer Company Information
    • 13.2.2 Pfizer Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.2.3 Pfizer Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 Pfizer Main Business Overview
    • 13.2.5 Pfizer Latest Developments
  • 13.3 AstraZeneca
    • 13.3.1 AstraZeneca Company Information
    • 13.3.2 AstraZeneca Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.3.3 AstraZeneca Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 AstraZeneca Main Business Overview
    • 13.3.5 AstraZeneca Latest Developments
  • 13.4 Bayer
    • 13.4.1 Bayer Company Information
    • 13.4.2 Bayer Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.4.3 Bayer Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 Bayer Main Business Overview
    • 13.4.5 Bayer Latest Developments
  • 13.5 Sun Pharma
    • 13.5.1 Sun Pharma Company Information
    • 13.5.2 Sun Pharma Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.5.3 Sun Pharma Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Sun Pharma Main Business Overview
    • 13.5.5 Sun Pharma Latest Developments
  • 13.6 Teva
    • 13.6.1 Teva Company Information
    • 13.6.2 Teva Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.6.3 Teva Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Teva Main Business Overview
    • 13.6.5 Teva Latest Developments
  • 13.7 Eisai Co.
    • 13.7.1 Eisai Co. Company Information
    • 13.7.2 Eisai Co. Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.7.3 Eisai Co. Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Eisai Co. Main Business Overview
    • 13.7.5 Eisai Co. Latest Developments
  • 13.8 Mylan
    • 13.8.1 Mylan Company Information
    • 13.8.2 Mylan Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.8.3 Mylan Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 Mylan Main Business Overview
    • 13.8.5 Mylan Latest Developments
  • 13.9 AOSAIKANG Pharma
    • 13.9.1 AOSAIKANG Pharma Company Information
    • 13.9.2 AOSAIKANG Pharma Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.9.3 AOSAIKANG Pharma Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.9.4 AOSAIKANG Pharma Main Business Overview
    • 13.9.5 AOSAIKANG Pharma Latest Developments
  • 13.10 Luoxin Pharma
    • 13.10.1 Luoxin Pharma Company Information
    • 13.10.2 Luoxin Pharma Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.10.3 Luoxin Pharma Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.10.4 Luoxin Pharma Main Business Overview
    • 13.10.5 Luoxin Pharma Latest Developments
  • 13.11 LIVZON
    • 13.11.1 LIVZON Company Information
    • 13.11.2 LIVZON Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.11.3 LIVZON Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.11.4 LIVZON Main Business Overview
    • 13.11.5 LIVZON Latest Developments
  • 13.12 Eastchina Pharma
    • 13.12.1 Eastchina Pharma Company Information
    • 13.12.2 Eastchina Pharma Proton Pump Inhibitors for Gastric Acid Therapy Product Offered
    • 13.12.3 Eastchina Pharma Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.12.4 Eastchina Pharma Main Business Overview
    • 13.12.5 Eastchina Pharma Latest Developments

14 Research Findings and Conclusion

Proton pump inhibitors (PPIs) reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the esophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the esophagus, stomach, and duodenum to heal.

The global market for Proton Pump Inhibitors for Gastric Acid Therapy is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Proton Pump Inhibitors for Gastric Acid Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Proton Pump Inhibitors for Gastric Acid Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Proton Pump Inhibitors for Gastric Acid Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Proton Pump Inhibitors for Gastric Acid Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Proton Pump Inhibitors for Gastric Acid Therapy players cover Takeda, Pfizer, AstraZeneca, Bayer and Sun Pharma, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Proton Pump Inhibitors for Gastric Acid Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Proton Pump Inhibitors for Gastric Acid Therapy market, with both quantitative and qualitative data, to help readers understand how the Proton Pump Inhibitors for Gastric Acid Therapy market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in Units.

Market Segmentation:
The study segments the Proton Pump Inhibitors for Gastric Acid Therapy market and forecasts the market size by Type (Dexlansoprazole, Esomeprazole and Lansoprazole), by Application (Hospital Pharmacy, Retail Pharmacy and Other,), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Dexlansoprazole
Esomeprazole
Lansoprazole
Omeprazole
Pantoprazole
Rabeprazole

Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Other

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Takeda
Pfizer
AstraZeneca
Bayer
Sun Pharma
Teva
Eisai Co.
Mylan
AOSAIKANG Pharma
Luoxin Pharma
LIVZON
Eastchina Pharma

Chapter Introduction
Chapter 1: Scope of Proton Pump Inhibitors for Gastric Acid Therapy, Research Methodology, etc.
Chapter 2: Executive Summary, global Proton Pump Inhibitors for Gastric Acid Therapy market size (sales and revenue) and CAGR, Proton Pump Inhibitors for Gastric Acid Therapy market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Proton Pump Inhibitors for Gastric Acid Therapy sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Proton Pump Inhibitors for Gastric Acid Therapy sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Proton Pump Inhibitors for Gastric Acid Therapy market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Takeda, Pfizer, AstraZeneca, Bayer, Sun Pharma, Teva, Eisai Co., Mylan and AOSAIKANG Pharma, etc.
Chapter 14: Research Findings and Conclusion
Buy now